NIH-Funding

Effects of In Utero Alcohol Exposure on Adult Health and Disease (R21 - Clinical Trial Optional)

NIH Funding Announcements - Tue, 12/19/2017 - 13:21
Funding Opportunity PA-18-508 from the NIH Guide for Grants and Contracts. Funding Opportunity Purpose This Funding Opportunity Announcement (FOA), issued by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), is intended to support novel research on how prenatal alcohol exposure may contribute to the etiology of chronic diseases and health conditions later in life. Central to this theme is the developmental origins of health and disease (DOHaD) concept which suggests that fetal adaptations in response to adverse intrauterine conditions may increase the risk for childhood and adulthood disease. The goal of this FOA is to stimulate a broad range of research to: 1) leverage existing prospective birth cohorts to define the role of maternal alcohol consumption in the DOHaD process; 2) investigate the biological, cellular, and molecular mechanisms by which prenatal alcohol exposure may impact disease outcomes later in life; and 3) identify biomarkers associated with gestational alcohol exposure that may predict adult disease susceptibility in exposed offspring. Studies supported by this FOA will provide fundamental insights into a possible fetal-basis to adult disease that is influenced by maternal alcohol use.
Categories: NIH-Funding

Effects of In Utero Alcohol Exposure on Adult Health and Disease (R01 - Clinical Trial Optional)

NIH Funding Announcements - Tue, 12/19/2017 - 13:20
Funding Opportunity PA-18-507 from the NIH Guide for Grants and Contracts. Funding Opportunity Purpose This Funding Opportunity Announcement (FOA), issued by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), is intended to support novel research on how prenatal alcohol exposure may contribute to the etiology of chronic diseases and health conditions later in life. Central to this theme is the developmental origins of health and disease (DOHaD) concept which suggests that fetal adaptations in response to adverse intrauterine conditions may increase the risk for childhood and adulthood disease. The goal of this FOA is to stimulate a broad range of research to: 1) leverage existing prospective birth cohorts to define the role of maternal alcohol consumption in the DOHaD process; 2) investigate the biological, cellular, and molecular mechanisms by which prenatal alcohol exposure may impact disease outcomes later in life; and 3) identify biomarkers associated with gestational alcohol exposure that may predict adult disease susceptibility in exposed offspring. Studies supported by this FOA will provide fundamental insights into a possible fetal-basis to adult disease that is influenced by maternal alcohol use.
Categories: NIH-Funding

Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp - Clinical Trial Not Allowed)

NIH Funding Announcements - Tue, 12/19/2017 - 13:11
Funding Opportunity PA-18-517 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) seeks to develop and nurture a national innovation ecosystem that builds upon biomedical research to develop technologies, products and services that benefit society. Toward meeting this objective, the I-Corps program is being offered. The I-Corps at NIH program is focused on educating researchers and technologists on how to translate technologies from the lab into the marketplace. Under this FOA, participating NIH and CDC Institutes and Centers will continue providing administrative supplement awards to currently-funded SBIR and STTR Phase I grantees. The program is designed to provide three-member project teams with access to instruction and mentoring in order to accelerate the translation of technologies currently being developed with NIH and CDC SBIR and STTR funding. It is anticipated that outcomes for the I-Corps teams participating in this program will include significantly refined commercialization plans and well-informed pivots in their overall commercialization strategies. Prospective applicants are strongly encouraged to contact NIH or CDC Scientific/Research staff for more information about the program before applying.
Categories: NIH-Funding

NIH Operates Under a Continuing Resolution Through December 22, 2017

NIH Funding Announcements - Tue, 12/19/2017 - 10:11
Notice NOT-OD-18-120 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R01- Clinical Trial Optional)

NIH Funding Announcements - Tue, 12/19/2017 - 10:07
Funding Opportunity RFA-DK-17-017 from the NIH Guide for Grants and Contracts. The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC), in collaboration with the International IBD Genetics Consortium, has identified about 200 susceptibility loci for IBD. The IBDGC has recently been awarded renewed funding to identify causal genes and genetic variants within these loci, and to elucidate the mechanisms through which they contribute to the pathophysiology of IBD. However, the IBDGC's current resources permit them to explore the functions of only a limited set of genes within a limited set of physiological domains. The purpose of this FOA is to expand the number of genes and range of IBD-related phenotypes and physiological domains under study by means of collaborations of the IBDGC with investigators with expertise complementary to that of their own members. Proposed studies must not duplicate studies either ongoing or already completed by the IBDGC. Multi-site clinical trials will not be considered responsive to this FOA.
Categories: NIH-Funding

Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R21 - Clinical Trial Optional)

NIH Funding Announcements - Tue, 12/19/2017 - 10:06
Funding Opportunity RFA-DK-17-018 from the NIH Guide for Grants and Contracts. The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC), in collaboration with the International IBD Genetics Consortium, has identified about 200 susceptibility loci for IBD. The IBDGC has recently been awarded renewed funding to identify causal genes and genetic variants within these loci, and to elucidate the mechanisms through which they contribute to the pathophysiology of IBD. However, the IBDGC's current resources permit them to explore the functions of only a limited set of genes within a limited set of physiological domains. The purpose of this FOA is to expand the number of genes and range of IBD-related phenotypes and physiological domains under study by means of collaborations of the IBDGC with investigators with expertise complementary to that of their own members. This FOA is intended to support highly exploratory studies which may require development and testing of novel experimental platforms or analytic methods. Proposed studies must not duplicate studies either ongoing or already completed by the IBDGC. Multi-site clinical trials will not be considered responsive to this FOA.
Categories: NIH-Funding

Notice Announcing the Removal of the Funding Pause for Gain-of-Function Research Projects

NIH Funding Announcements - Tue, 12/19/2017 - 10:00
Notice NOT-OD-17-071 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Human Cell Biology of Alzheimer's Disease Genetic Variants (R01 - Clinical Trial Not Allowed)

NIH Funding Announcements - Tue, 12/19/2017 - 03:38
Funding Opportunity PAR-18-516 from the NIH Guide for Grants and Contracts. The goal of this FOA is to establish functional genotype-phenotype relationships of genetic variants, suspected of altering the risk of Alzheimers disease (AD), in neural cells using human induced pluripotent stem cells or other human cell reprogramming approaches. The causal linkage of AD-associated genetic variants identified in genome-wide association studies and genome sequencing studies to molecular and biological cell phenotypes in human neural cells is expected to give greater insight into molecular targets contributing to the etiology of AD. Studies of human genetics in human cells is essential to understanding the etiology of AD.
Categories: NIH-Funding

Discovery of Molecular Targets for Pregnancy-Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (R01 - Clinical Trial Optional)

NIH Funding Announcements - Tue, 12/19/2017 - 02:02
Funding Opportunity PAR-18-511 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage grant applications that will identify molecular targets for pregnancy associated/induced disorders and will lead to the development of new safer and more effective medications for use in pregnancy.
Categories: NIH-Funding

Drug Repurposing for Conditions Affecting Neonates and Pregnant Women (R01 - Clinical Trial Optional)

NIH Funding Announcements - Mon, 12/18/2017 - 13:55
Funding Opportunity PAR-18-506 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to repurpose already FDA approved drugs for new neonatal and obstetric indications, in order to overcome the difficulties associated with the traditional development of drugs appropriate for use in neonates and pregnant women and facilitate treatment of these vulnerable populations.
Categories: NIH-Funding

Community Partnerships to Advance Research (CPAR) (R21 Clinical Trial Optional)

NIH Funding Announcements - Mon, 12/18/2017 - 13:20
Funding Opportunity PA-18-381 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages researchers to partner with community groups, using Community Engaged Research (CEnR) methodologies that will enhance relationships and lead to better intervention development and positive health outcomes.
Categories: NIH-Funding

Community Partnerships to Advance Research (CPAR) (R01 Clinical Trial Optional)

NIH Funding Announcements - Mon, 12/18/2017 - 13:20
Funding Opportunity PA-18-377 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages researchers to partner with community groups, using Community Engaged Research (CEnR) methodologies that will enhance relationships and lead to better intervention development and positive health outcomes.
Categories: NIH-Funding

Community Partnerships to Advance Research (CPAR) (R15 Clinical Trial Not Allowed)

NIH Funding Announcements - Mon, 12/18/2017 - 13:19
Funding Opportunity PA-18-475 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages researchers to partner with community groups, using Community Engaged Research (CEnR) methodologies that will enhance relationships and lead to better intervention development and positive health outcomes.
Categories: NIH-Funding

Advancing Basic Neurobiology Toward Translation Through Assay Development (R01 Clinical Trials Not Allowed)

NIH Funding Announcements - Mon, 12/18/2017 - 13:18
Funding Opportunity PAR-18-505 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages research grant applications to develop novel, robust assays to reveal changes in neuronal and/or glial function. The goal is to adapt state-of-the-art measures of basic cellular processes or molecular events that are key mediators of nervous system function into phenotypic assays, with the intent to probe mechanisms or perturbations in an unbiased and efficient manner. These novel assays would provide opportunities to measure neurobiological endpoints to accelerate basic discovery and support target identification and therapeutic development efforts.
Categories: NIH-Funding